Plasminogen activator inhibitor-1 antigen levels are related to gamma glutamyl transferase in hyperlipidaemic women

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 7, Issue 5, 1997, Pages 371-375

  Bastard, J P ^a   Bruckert, E ^a   Giral, P ^a   Beucler, I ^a   Ankri, A ^a   Hainque, B ^a,b   Turpin, G ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Gamma glutamyl transferase; Hyperlipidaemia; Insulin resistance; Plasminogen activator inhibitor 1 (PAI 1)

Indexed keywords

EID: 0008925223     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Declerck PJ, Juhan-Vague I, Felez J, Wiman B (1994) Pathophysiology of fibrinolysis. J Intern Med 236: 425-432
2. Juhan-Vague I, Alessi MC, Nalbone G (1993) Fibrinolysis and atherothrombosis. Curr Opin Lipidol 4: 477-483
3. Hamsten A, de Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, Blomback M, Wiman B (1987) Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 2: 3-9
4. Vague P, Juhan-Vague I, Chabert V, Alessi MC, Atlan C (1989) Fat distribution and plasminogen activator inhibitor activity in non diabetic obese women. Metabolism 38: 913-915
5. Juhan-Vague I, Roul C, Alessi MC, Ardissone JP, Heim M, Vague P (1989) Increased plasminogen activator inhibitor activity in non insulin dependent diabetic patients. Relationship with plasma insulin. Thromb Haemostas 61: 370-373
6. Juhan-Vague I, Alessi MC, Vague P (1991) Increased plasma plasminogen inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis. Diabetologia 34: 457-462
7. Van Steenbergen W, Lanckmans S (1995) Liver disturbances in obesity and diabetes mellitus. Int J Obesity 19 (Sup 3): S27-S36
8. Alessi MC, Parrot G, Guenoun E, Scelles V, Vague P (1995) Relationship between PAI activity and adipsin levels. Thromb Haemostas 74:1200-1202
9. Samad F, Yamamoto K, Loskutoff DJ (1996) Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo: induction by tumor necrosis factor-α and lipopolysaccharide. J Clin Invest 97: 37-46
10. Lundgren CH, Brown SL, Nordt TK, Sobel BE, Fujii S (1996) Elaboration of type-1 plasminogen activator inhibitor from adipocytes: a potential pathogenetic link between obesity and cardiovascular disease. Circulation 93:106-110
11. Bruckert E, Ankri A, Giral P, Turpin G (1994) Relationship between plasminogen activator inhibitor-1 and hepatic enzyme concentrations in hyperlipidaemic patients. Thromb Haemostas 72: 434-437
12. Asplun-Carlson A, Hamsten A, Wiman B, Carlson LA (1993) Relationship between plasminogen activator inhibitor-1 activity and VLDL triglyceride concentration, insulin levels and insulin sensitivity: studies in randomly selected normo- and hypertriglyceridaemic men. Diabetologia 36: 817-825
13. Schiele F, Guilmin AM, Detienne H, Siest G (1977) Gamma glutamyl transferase activity in plasma: statistical distributions, individual variations and reference intervals. Clin Chem 23:1023-1028
14. Nilssen O, Førde OH, Brenn T (1990) The TROMSØ study: Distribution and population determinants of gamma glutamyl transferase. Am J Epidemiol 132: 318-326
15. Mykkänen L, Rönnemaa T, Marniemi J, Haffner SM, Bergman R, Laasko M (1994) Insulin sensitivity is not an independent determinant of plasminogen activator inhibitor-1 activity. Arterioscler Thromb 14:1264-1271
16. National Diabetes Data Group (1979) Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 28:1039-1057
17. Duncan MH, Singh BM, Wise PH, Carter G, Alaghband-Zadeh J (1995) A simple measure of insulin resistance. Lancet 346:120-121
18. Bastard JP, Grimaldi A, Jardel C, Porquet D, Bruckert E, Hainque B (1997) A simple index of insulin resistance. Diabetes Metab (in press)
19. Fruchart JC, Beucler I, Blaton V, Canal J, Douste-Blazy L, Gambert P, Katerman R, Legrand A, Polonowski J, Steinmmetz J, Thouvenot JP (1982) Méthode sélectionnée pour le dosage du cholestérol des lipoprotéines non précipitables par le phosphotungstate de sodium en présence de chlorure de magnésium. Inf Scient Biol 8: 69-72
20. Potter Van Loon BJ, Kluft C, Radder JK, Blankenstein MA, Meinders AE (1993) The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance. Metabolism 42: 945-949
21. Bastard JP, Bruckert E, Porquet D, Jardel C, Ankri A, Delattre J, Hainque B (1996) Evidence for a relationship between plasminogen activator inhibitor-1 and gamma glutamyl transferase. Thromb Res 81: 271-275
22. Bastard JP, Bruckert E, Robert JJ, Ankri A, Grimaldi A, Jardel C, Hainque B (1995) Are free fatty acids related to plasma plasminogen activator inhibitor 1 in android obesity? Int J Obesity 19: 836-838
23. Brussard HE, Gevers Leuven JA, Krans HMJ, Meijer P, Buytenhek R, Kluft C (1994) Non-esterified fatty acids are related with hypofibrinolysis in type 2 diabetes mellitus. Fibrinolysis 8 (Suppl. 2): 25-27